# Metformin - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Metformin is an established first-line biguanide for type 2 diabetes that activates AMPK and reduces hepatic gluconeogenesis. Epidemiological data in diabetics suggests lower cancer and cardiovascular mortality. However, recent human RCTs in healthy, non-diabetic adults reveal it blunts aerobic VO2 max improvements and mitochondrial adaptations to exercise.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **83/100**
- **Evidence Quality Tier**: **bronze**
- **Human Clinical Evidence Strength**: 91/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 82/100 (Higher is safer)
- **Time Burden**: ~1 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 2/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Immense diabetic clinical dataset and low cost; however, clear human trial evidence of exercise blunting significantly lowers its suitability for already-fit individuals.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Heart Health & Endothelial Function**: **0/100** [Rank #131 of 133 in Heart] - Effect: Neutral
    - Mechanism: No direct primary biochemical modulation of heart health; pathway is neutral for Metformin.
- **Brain Longevity & Neuroprotection**: **0/100** [Rank #139 of 141 in Brain] - Effect: Neutral
    - Mechanism: No direct primary biochemical modulation of brain longevity; pathway is neutral for Metformin.
- **Metabolic Flexibility & Glycemic Control**: **0/100** [Rank #125 of 129 in Metabolic] - Effect: Neutral
    - Mechanism: No direct primary biochemical modulation of metabolic health; pathway is neutral for Metformin.
- **Cancer Defense & DNA Repair**: **0/100** [Rank #112 of 120 in Cancer Defense] - Effect: Neutral
    - Mechanism: No direct primary biochemical modulation of cancer defense; pathway is neutral for Metformin.
- **Endocrine & Anabolic Balance**: **0/100** [Rank #113 of 120 in Endocrine] - Effect: Neutral
    - Mechanism: No direct primary biochemical modulation of testosterone; pathway is neutral for Metformin.
- **Chronic Inflammation Reduction**: **0/100** [Rank #125 of 126 in Inflammation] - Effect: Neutral
    - Mechanism: No direct primary biochemical modulation of chronic inflammation; pathway is neutral for Metformin.
- **Bone Density & Connective Matrix**: **0/100** [Rank #134 of 142 in Bone Matrix] - Effect: Neutral
    - Mechanism: No direct primary biochemical modulation of bone density; pathway is neutral for Metformin.
- **Cellular Longevity & Autophagy**: **0/100** [Rank #131 of 131 in Cellular] - Effect: Neutral
    - Mechanism: No direct primary biochemical modulation of cellular longevity; pathway is neutral for Metformin.

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: Refer to individualized clinical assessment
- **Recommended Timing**: Consistent daily schedule
- **Administration Type**: Behavioral / Compound
- **Recommended Biomarkers to Monitor**: metabolic_health, satiety, energy, bone_density, heart_health, testosterone

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: Severe renal impairment (eGFR <30 mL/min/1.73m²), Metabolic or lactic acidosis, Severe hepatic dysfunction, Contrast dye procedures within 48 hours
- **Safety Profile**: High Margin - Gastrointestinal upset (diarrhea, bloating, nausea); Vitamin B12 malabsorption with long-term use

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Metformin increases satiety and reduces daily caloric intake in obese subjects** [PMID: 9550138]
   - Link: https://pubmed.ncbi.nlm.nih.gov/9550138/
2. **Metformin improves peripheral insulin sensitivity and stabilizes daytime postprandial fatigue** [PMID: 25458925]
   - Link: https://pubmed.ncbi.nlm.nih.gov/25458925/
3. **Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (DPP)** [PMID: 11986341]
   - Link: https://pubmed.ncbi.nlm.nih.gov/11986341/
4. **Effect of intensive blood-glucose control with metformin on complications in overweight type 2 diabetes** [PMID: 9742977]
   - Link: https://pubmed.ncbi.nlm.nih.gov/9742977/
5. **Can people with type 2 diabetes live longer than those without? A cohort study comparing metformin with other therapies** [PMID: 25041462]
   - Link: https://pubmed.ncbi.nlm.nih.gov/25041462/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Metformin on LongevityReviews](https://longevityreviews.org/modalities/metformin)
- **Last Evidence Calibration**: 2026-09-09
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.